» Articles » PMID: 30505817

Status of - Fusion in Prostate Cancer Patients from India: Correlation with Clinico-pathological Details and Met160Val Polymorphism

Overview
Journal Prostate Int
Date 2018 Dec 4
PMID 30505817
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Prostate cancer (PCa) shows considerable clinical heterogeneity that has been primarily attributed to variable molecular alterations. - fusion is one such molecular subtype that has been associated with predominantly poor prognosis. More recently, a single nucleotide polymorphism (SNP) in the gene rs12329760 C>T (Met160Val) has been shown to positively correlate with the fusion status and also to be associated with increased risk for PCa. The aim of the present study is to determine the frequency of - fusion and association of rs12329760 in Indian PCa patients with fusion status.

Methods: - fusion by fluorescence hybridization was determined in 102 of 150 PCa biopsy-proven cases. Genotyping for rs12329760 was performed on the entire cohort of 150 cases by Sanger sequencing.

Results: - fusion was seen in 27 of 102 (26%) cases. Fusion-positive patterns in this study showed fusion by translocation in nine of 27 cases (33.5%), by deletion in six of 27 (22%) cases, and by insertion in 12 of 27 cases (44.5%). No association of the fusion status with Gleason Score, pattern, or perineural invasion was seen. The SNP rs12329760 'T' allele was prevalent with a frequency of 0.27 in the PCa patients. The SNP was significantly associated with fusion [odds ratio (OR) = 2.176, 95% confidence interval (CI) = 1.012-4.684,  = 0.04], more specifically fusion by deletion ( = 0.04).

Conclusion: The results provided here determine the frequency of - fusions (26%) in a fairly large cohort of Indian PCa cases and also the association of rs12329760 SNP with - fusion. No association with other clinico-pathological features was observed. Future studies with clinical outcomes are warranted in this population.

Citing Articles

Acquired copy number variation in prostate tumours: a review of common somatic copy number alterations, how they are formed and their clinical utility.

OMalley D, Raspin K, Melton P, Burdon K, Dickinson J, FitzGerald L Br J Cancer. 2023; 130(3):347-357.

PMID: 37945750 PMC: 10844642. DOI: 10.1038/s41416-023-02485-7.


Allelic Variations in the Human Genes and and the Resistance to Viral Infection by SARS-CoV-2.

Vitello G, Federico C, Bruno F, Vinci M, Musumeci A, Ragalmuto A Int J Mol Sci. 2022; 23(16).

PMID: 36012436 PMC: 9409186. DOI: 10.3390/ijms23169171.


Molecular mechanisms involved in anosmia induced by SARS-CoV-2, with a focus on the transmembrane serine protease TMPRSS2.

Karimian A, Behjati M, Karimian M Arch Virol. 2022; 167(10):1931-1946.

PMID: 35939103 PMC: 9358639. DOI: 10.1007/s00705-022-05545-0.


Analysis of ACE2 and TMPRSS2 coding variants as a risk factor for SARS-CoV-2 from 946 whole-exome sequencing data in the Turkish population.

Duman N, Tuncel G, Bisgin A, Bozdogan S, Sag S, Gul S J Med Virol. 2022; 94(11):5225-5243.

PMID: 35811452 PMC: 9349697. DOI: 10.1002/jmv.27976.


Initial study on TMPRSS2 p.Val160Met genetic variant in COVID-19 patients.

Wulandari L, Hamidah B, Pakpahan C, Damayanti N, Kurniati N, Adiatmaja C Hum Genomics. 2021; 15(1):29.

PMID: 34001248 PMC: 8127183. DOI: 10.1186/s40246-021-00330-7.


References
1.
Giri V, Ruth K, Hughes L, Uzzo R, Chen D, Boorjian S . Racial differences in prediction of time to prostate cancer diagnosis in a prospective screening cohort of high-risk men: effect of TMPRSS2 Met160Val. BJU Int. 2010; 107(3):466-70. PMC: 3052292. DOI: 10.1111/j.1464-410X.2010.09522.x. View

2.
Tu J, Rohan S, Kao J, Kitabayashi N, Mathew S, Chen Y . Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Mod Pathol. 2007; 20(9):921-8. DOI: 10.1038/modpathol.3800903. View

3.
Darnel A, LaFargue C, Vollmer R, Corcos J, Bismar T . TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort. Cancer Biol Ther. 2008; 8(2):125-30. DOI: 10.4161/cbt.8.2.7134. View

4.
Lapointe J, Kim Y, Miller M, Li C, Kaygusuz G, van de Rijn M . A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Mod Pathol. 2007; 20(4):467-73. DOI: 10.1038/modpathol.3800759. View

5.
Esgueva R, Perner S, LaFargue C, Scheble V, Stephan C, Lein M . Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort. Mod Pathol. 2010; 23(4):539-46. PMC: 2848699. DOI: 10.1038/modpathol.2009.193. View